Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase III study of Keytruda in HNSCC misses primary endpoint

July 26, 2017

Pfizer reports results from phase III study of bevacizumab biosimilar

July 25, 2017

FDA accepts sBLAs for Opdivo 4-week dosing schedule

July 25, 2017

FDA expands Yervoy indication to include pediatric patients

July 25, 2017

Seattle Genetics enters clinical collaboration with Genentech

July 25, 2017

Dana-Farber Cancer Institute begins phase I study of rQNestin34.5v.2 for recurrent malignant glioma

July 25, 2017

EMA committee recommends approvals for Tecentriq in NSCLC and metastatic urothelial carcinoma

July 24, 2017

EMA's CHMP recommends approval of Gazyvaro for previously untreated advanced follicular lymphoma

July 24, 2017

CHMP recommends approval of avelumab for metastatic Merkel cell carcinoma

July 24, 2017

CHMP grants positive opinion for Keytruda in urothelial carcinoma

July 24, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 21, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 21, 2026
New biomarker may improve RSV drug screening
BioWorld
Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The...